2014
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study
Bancroft E, Page E, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster C, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans D, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney L, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick P, Bojesen A, Skytte A, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams W, Oosterwijk J, Blanco I, Salinas M, Cook J, Rosario D, Buys S, Conner T, Ausems M, Ong K, Hoffman J, Domchek S, Powers J, Teixeira M, Maia S, Foulkes W, Taherian N, Ruijs M, Enden A, Izatt L, Davidson R, Adank M, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman G, Zgajnar J, Tischkowitz M, Clowes V, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady A, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor D, Copakova L, Barwell J, Giri V, Murthy V, Nicolai N, Teo S, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Killick E, Collaborators T, Moss S, Eeles R. Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology 2014, 66: 489-499. PMID: 24484606, PMCID: PMC4105321, DOI: 10.1016/j.eururo.2014.01.003.Peer-Reviewed Original ResearchConceptsPositive predictive valueHigh-risk diseaseBRCA2 mutation carriersProstate cancerTargeted prostate cancerMutation carriersBRCA1/2 mutationsHigh riskProstate-specific antigen (PSA) testingProstate cancer screeningScreening resultsGermline BRCA1/2 mutationsFisher's exact testInitial screening roundGermline genetic markersIdentification of tumorsBreast cancer 1Germline genetic risk variantsBreast cancer 2PCa incidencePSA levelsAntigen testingTumor characteristicsAggressive diseaseBRCA2 carriers
2013
Validation of association of genetic variants at 10q with prostate‐specific antigen (PSA) levels in men at high risk for prostate cancer
Chang B, Hughes L, Chen D, Gross L, Ruth K, Giri V. Validation of association of genetic variants at 10q with prostate‐specific antigen (PSA) levels in men at high risk for prostate cancer. BJU International 2013, 113: e150-e156. PMID: 23937305, PMCID: PMC3830710, DOI: 10.1111/bju.12264.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramHigh-risk groupPSA levelsCaucasian manProstate cancerFamily historyProstate cancer screening strategiesProstate cancer screening studyCancer Risk Assessment ProgramBaseline PSA levelsTaqMan single nucleotide polymorphismCancer screening strategiesCancer screening studySingle nucleotide polymorphismsAfrican American ethnicityAllele carrier statusBRCA gene mutationsPotential confoundersAge 35Eligibility criteriaClinical relevanceT alleleRisk assessment programA alleleCarrier status
2009
Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population
Kaplan D, Boorjian S, Ruth K, Egleston B, Chen D, Viterbo R, Uzzo R, Buyyounouski M, Raysor S, Giri V. Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high‐risk screening population. BJU International 2009, 105: 334-337. PMID: 19709072, PMCID: PMC2809782, DOI: 10.1111/j.1464-410x.2009.08793.x.Peer-Reviewed Original ResearchConceptsProstate Cancer Risk Assessment ProgramProstate Cancer Prevention Trial Risk CalculatorProstate cancer riskHigh-risk menProstate cancerPSA levelsRisk scoreFamily historyAfrican American menPCPT calculatorRisk calculatorCancer riskLower baseline prostate-specific antigen levelsBaseline prostate-specific antigen levelLow baseline PSA levelsProstate-specific antigen levelCancer Risk Assessment ProgramBaseline PSA levelsMedian PSA levelRisk of diagnosisBaseline risk scoreMedian risk scoreProstate cancer ratesProstate cancer diagnosisPrevious biopsy